Course Experts: Hannah McDermott, PharmD

Course Description: This course prepares pharmacists to evaluate the safe and evidence-based use of herbal products and dietary supplements in oncology care for symptom management and supportive treatment. Participants will assess safety considerations, review the available clinical evidence, and develop patient-centered recommendations based on efficacy and toxicity data.

Course Experts: Lara Abousamra, PharmD, BCPS, BCOP and Victoria Grant, PharmD, BCIDP

Course Description: This course outlines specific recommendations regarding vaccine selection and timing in patients receiving cellular therapies, including strategies to ensure successful revaccination.

Course Experts: Victoria Grant, PharmD, BCIDP and Kelly Pane, PharmD

Course Description: This course outlines general principles and recommendations regarding vaccines in the general cancer patient, and reviews data of vaccines that target seasonal respiratory viruses.

Course Experts: Josh Zhang, PharmD; Eno Inyang, PharmD, BCPS, BCOP; Emily Tiao, PharmD, BCOP

Course Description: This course outlines the pathophysiology, diagnosis, and treatment of patients with Acute Promyelocytic Leukemia (APL), as well as reviews pertinent literature and patient considerations.

Course Experts: Julia Jandro, PharmD

Course Description: This course equips pharmacists with practical knowledge to optimize the management of adult patients with soft tissue sarcoma (STS). Participants will review clinically relevant sarcoma subtypes, first-line treatment strategies, targeted therapies, and STS-specific agents to support evidence-based therapeutic decision-making.

Course Experts: Abigail Thomas, PharmD, BCPMP; Molly Bacon, PharmD, BCPMP; Benjamin Kematick, PharmD, BCACP, BCPMP; Bridget Scullion, PharmD, BCOP, FPPCP

Course Description: This pharmacy law course examines the history, evolving legal landscape, and therapeutic potential of psychedelics, with a focus on their clinical and non-clinical applications and emerging role in pain management. Participants will review proposed mechanisms of action, current regulatory consid...

Course Experts: Mishra, PharmD and Patrick McBride, PharmD, BCOP

Course Description: This course describes the mechanism of action and efficacy of asparaginase in targeting acute lymphoblastic leukemia (ALL) cell. It identifies asparaginase adverse effects and enables learners to design a safe and effective treatment plan for patients with ALL.

Course Experts: Josh Zhang, PharmD; Ashka Patel, PharmD, BCOP

Course Description: This course offers a comprehensive overview of Classical Hodgkin Lymphoma (cHL), covering its pathophysiology, diagnosis, and staging. Learners will explore current treatment principles, evaluate novel therapies, and apply these insights to patient cases. The course also examines emerging treatments and their potential to shape the future of cHL care, empowering healthcare professional...

Course Experts: Sandra Savaya, PharmD

Course Description: This course reviews the background information and pathophysiology of chronic lymphocytic leukemia (CLL), compares Bruton tyrosine kinase (BTK) inhibitors for CLL, and outlines the future of CLL treatment using new therapies.
Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib...

Course Experts: Beata Rucinski, PharmD and Jean Connors, MD

Course Description: This course describes the place in therapy of direct oral anticoagulants (DOACs) in cancer associated VTEs and reviews the evidence that influences cancer associated anticoagulation guidelines.
Venous Thromboembolism (VTE), Anticoagulation, Direct Oral Anticoagulants (DOACs), Collaborative Drug Therapy Management (CDTM), Anticoagulation Management Service (AMS), Deep Vein ...

Course Experts: Niti Patel, PharmD

Course Description: This course reviews new agents and new indications for treatment of metastatic breast cancer, as well as how to navigate the new algorithm of treating metastatic breast cancer based on recently published literature.
Metastatic, Breast Cancer, HER2, Hormone Receptor (HR), Triple Negative Breast Cancer (TNBC), Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), De Novo, Lymph Node...

Course Experts: Brian Thomson, PharmD and Angela Chen, PharmD, BCPS

Course Description: This course reviews USP <800> and recommended best practices for developing a comprehensive and compliant hazardous drug program.
USP 800, Hazardous Drugs (HDs), Sterile Compounding, Personnel Training, Engineering Controls, C-PEC (Containment Primary Engineering Control), C-SEC (Containment Secondary Engineering Control), C-SCA (Containment Sterile Compoundi...